<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245865</url>
  </required_header>
  <id_info>
    <org_study_id>Toco-CoR</org_study_id>
    <nct_id>NCT04245865</nct_id>
  </id_info>
  <brief_title>Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer</brief_title>
  <acronym>Toco-CoR</acronym>
  <official_title>Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double blind, randomized phase II trial will investigate whether the addition of
      tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and
      bevacizumab. Half of the patients will receive tocotrienol and the other half placebo.
      Treatment is planned for a period of maximum six months and will be discontinued earlier in
      case of progression or unacceptable toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of progression free patients at six months</measure>
    <time_frame>Six months after enrollment of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first serious adverse event according to CTCAE 5.0</measure>
    <time_frame>Six months after enrollment of the last patient</time_frame>
    <description>CTCAE=Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate as measured by RECIST 1.1</measure>
    <time_frame>Six months after enrollment of the last patient</time_frame>
    <description>RECIST=Response evaluation criteria in solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after enrollment of the last patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A, standard treatment + tocotrienol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + tocotrienol OR capecitabine + bevacizumab + tocotrienol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, standard treatment + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fluorouracil + calcium folinate + oxaliplatin + bevacizumab + placebo OR capecitabine + bevacizumab + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>2800 mg/m2 iv</description>
    <arm_group_label>Arm A, standard treatment + tocotrienol</arm_group_label>
    <arm_group_label>Arm B, standard treatment + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium folinate</intervention_name>
    <description>400 mg/m2 iv</description>
    <arm_group_label>Arm A, standard treatment + tocotrienol</arm_group_label>
    <arm_group_label>Arm B, standard treatment + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m2 iv</description>
    <arm_group_label>Arm A, standard treatment + tocotrienol</arm_group_label>
    <arm_group_label>Arm B, standard treatment + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg OR 7.5 mg/kg iv</description>
    <arm_group_label>Arm A, standard treatment + tocotrienol</arm_group_label>
    <arm_group_label>Arm B, standard treatment + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2 orally daily for two weeks</description>
    <arm_group_label>Arm A, standard treatment + tocotrienol</arm_group_label>
    <arm_group_label>Arm B, standard treatment + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol</intervention_name>
    <description>300 mg orally x 3 daily</description>
    <arm_group_label>Arm A, standard treatment + tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo orally x 3 daily</description>
    <arm_group_label>Arm B, standard treatment + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histopathologically verified adenocarcinoma of the colon or rectum

          -  Metastatic disease

          -  Planned treatment with FOLFOX or capecitabine combined with bevacizumab

          -  Evaluable disease according to RECIST 1.1

          -  Performance status 0-2

          -  Expected survival ≥ 3 months

          -  Patient acceptance to collection of blood samples for translational research

          -  Age ≥ 18 years

          -  Contraception during and 6 months after last dose for women of childbearing potential
             (less than one year amenorrhea and not undergone hysterectomy, bilateral salpingectomy
             or bilateral oophorectomy) and for male patients with a fertile partner. Hormonal
             contraception, intrauterine device, intrauterine hormone-releasing system, bilateral
             tubal occlusion, vasectomized partner, or sexual abstinence is accepted.

          -  Adequate bone marrow function, liver function, and renal function (within 7 days prior
             to inclusion):

               -  WBC ≥ 3.0 x 109/l or neutrophils (ANC) ≥ 1.5 x 10^9/l

               -  Platelet count ≥ 100 x 10^9/l

               -  Hemoglobin ≥ 6.0 mmol/l

               -  Serum bilirubin ≤ 2.0 x ULN

               -  Serum transaminase ≤ 2.5 x ULN

               -  Serum creatinine ≤ 1.5 ULN

          -  Urine dipstick for protein ≤ 2+, if the dipstick shows protein ≥ 2+, 24 hour urine
             testing must be performed and show protein contents ≤ 1g.

          -  Written and orally informed consent

        Exclusion Criteria:

          -  Other active malignant disease within 5 years prior to inclusion in the study.

          -  Other experimental therapy within 28 days prior to treatment initiation.

          -  Underlying medical disease not adequately treated.

          -  Surgery, including open biopsy, within 4 weeks prior to first dose of bevacizumab.

          -  Cerebral vascular attack, transient ischemic attack or subarachnoid hemorrhage within
             six months before start of treatment

          -  Bleeding tumor

          -  Pregnant or breastfeeding women

          -  Fertile patients not willing to use effective methods of contraception during
             treatment and for six months after end of treatment.

          -  Hypersensitivity to one or more active substances or auxiliary substances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torben F Hansen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital - University Hospital of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natacha Trabjerg, MD</last_name>
    <phone>+45 7940 5446</phone>
    <email>Natacha.dencker.trabjerg2@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natacha Trabjerg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Tocotrienol</keyword>
  <keyword>Natural killer cells</keyword>
  <keyword>Circulating tumor DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

